| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/16/2023 | 31.87% | Oppenheimer | $5.5 → $6 | Maintains | Outperform |
| 11/16/2023 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 09/22/2023 | 163.74% | HC Wainwright & Co. | → $12 | Reiterates | Buy → Buy |
| 09/06/2023 | 163.74% | HC Wainwright & Co. | → $12 | Reiterates | Buy → Buy |
| 08/24/2023 | 163.74% | HC Wainwright & Co. | → $12 | Reiterates | Buy → Buy |
| 08/21/2023 | 163.74% | HC Wainwright & Co. | → $12 | Reiterates | Buy → Buy |
| 06/05/2023 | 163.74% | HC Wainwright & Co. | → $12 | Reiterates | Buy → Buy |
| 05/18/2023 | 9.89% | Oppenheimer | → $5 | Reiterates | Outperform → Outperform |
| 05/18/2023 | -34.07% | Raymond James | $3.75 → $3 | Maintains | Outperform |
| 04/13/2023 | 163.74% | HC Wainwright & Co. | $13 → $12 | Maintains | Buy |
| 02/01/2023 | 185.71% | HC Wainwright & Co. | → $13 | Reiterates | → Buy |
| 12/12/2022 | 185.71% | HC Wainwright & Co. | $16 → $13 | Maintains | Buy |
| 11/21/2022 | -17.58% | Raymond James | $8 → $3.75 | Maintains | Outperform |
| 11/17/2022 | 9.89% | Northland Capital Markets | $15 → $5 | Maintains | Outperform |
| 08/22/2022 | 251.65% | HC Wainwright & Co. | $15 → $16 | Maintains | Buy |
| 08/11/2022 | 75.82% | Raymond James | $10 → $8 | Maintains | Outperform |
| 05/12/2022 | 119.78% | Raymond James | $12 → $10 | Maintains | Outperform |
| 03/03/2022 | 229.67% | Loop Capital | → $15 | Initiates Coverage On | → Buy |
| 11/29/2021 | 229.67% | HC Wainwright & Co. | $14 → $15 | Maintains | Buy |
| 08/12/2021 | 207.69% | HC Wainwright & Co. | $17 → $14 | Maintains | Buy |
| 07/19/2021 | 273.63% | HC Wainwright & Co. | → $17 | Initiates Coverage On | → Buy |
| 04/20/2021 | 229.67% | Northland Capital Markets | → $15 | Initiates Coverage On | → Outperform |
| 03/26/2021 | 229.67% | Oppenheimer | $13 → $15 | Maintains | Outperform |
| 02/17/2021 | 163.74% | Raymond James | $9 → $12 | Maintains | Outperform |
| 08/13/2020 | 97.8% | Raymond James | $10 → $9 | Maintains | Outperform |
| 03/24/2020 | 97.8% | Raymond James | $13 → $9 | Maintains | Outperform |
| 03/24/2020 | 185.71% | Cantor Fitzgerald | $17 → $13 | Reiterates | → Overweight |
| 11/26/2019 | 185.71% | Raymond James | $14 → $13 | Maintains | Outperform |
| 05/13/2019 | 273.63% | Oppenheimer | → $17 | Initiates Coverage On | → Outperform |
| 05/13/2019 | 273.63% | Cantor Fitzgerald | → $17 | Initiates Coverage On | → Overweight |
| 05/13/2019 | 207.69% | Raymond James | → $14 | Initiates Coverage On | → Outperform |
What is the target price for BrainsWay (BWAY)?
The latest price target for BrainsWay (NASDAQ: BWAY) was reported by Oppenheimer on November 16, 2023. The analyst firm set a price target for $6.00 expecting BWAY to rise to within 12 months (a possible 31.87% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BrainsWay (BWAY)?
The latest analyst rating for BrainsWay (NASDAQ: BWAY) was provided by Oppenheimer, and BrainsWay maintained their outperform rating.
When is the next analyst rating going to be posted or updated for BrainsWay (BWAY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BrainsWay, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BrainsWay was filed on November 16, 2023 so you should expect the next rating to be made available sometime around November 16, 2024.
Is the Analyst Rating BrainsWay (BWAY) correct?
While ratings are subjective and will change, the latest BrainsWay (BWAY) rating was a maintained with a price target of $5.50 to $6.00. The current price BrainsWay (BWAY) is trading at is $4.55, which is out of the analyst's predicted range.
